Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: PL 08265/0003Daiichi Sankyo UK Ltd., 1<sup>st</sup> Floor, Building 4, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH
Pharmacotherapeutic group: Acetic acid derivatives and related substances
ATC code: M01AB05
Motifene is a non-steroidal agent with marked analgesic/anti-inflammatory properties.
It is an inhibitor of prostaglandin synthetase (cyclo-oxygenase).
Diclofenac sodium is rapidly absorbed from the gut and is subject to first-pass metabolism. Therapeutic plasma concentrations occur about ½ hour after administration of Motifene. The active substance is 99.7% protein bound and the plasma half-life for the terminal elimination phase is 1-2 hours. Approximately 60% of the administered dose is excreted via the kidneys in the form of metabolites and less than 1% in unchanged form. The remainder of the dose is excreted via the bile in metabolised form.
Following rapid gastric passage, the gastro-resistant pellet component of Motifene ensures quick availability of the active component in the blood stream. The prolonged release pellets cause a delayed release of the active component, which means one single daily dose is usually sufficient.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
